Kathleen Claes

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7584033/publications.pdf

Version: 2024-02-01

163	9,974	28242 55	43868 91
papers	citations	h-index	g-index

174	174	174	14884
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Breast-Cancer Risk in Families with Mutations in PALB2. New England Journal of Medicine, 2014, 371, 497-506.	13.9	745
2	Association of Type and Location ofBRCA1andBRCA2Mutations With Risk of Breast and Ovarian Cancer. JAMA - Journal of the American Medical Association, 2015, 313, 1347.	3.8	390
3	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 2017, 49, 680-691.	9.4	356
4	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nature Genetics, 2017, 49, 1767-1778.	9.4	289
5	Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families. Journal of Clinical Oncology, 2020, 38, 674-685.	0.8	270
6	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. Nature Genetics, 2020, 52, 572-581.	9.4	265
7	Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk. PLoS Genetics, 2013, 9, e1003212.	1.5	244
8	Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers. Journal of the National Cancer Institute, 2017, 109, .	3.0	242
9	Mutational spectrum in a worldwide study of 29,700 families withBRCA1orBRCA2mutations. Human Mutation, 2018, 39, 593-620.	1.1	224
10	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics, 2015, 47, 164-171.	9.4	221
11	Fluid Status in Peritoneal Dialysis Patients: The European Body Composition Monitoring (EuroBCM) Study Cohort. PLoS ONE, 2011, 6, e17148.	1.1	216
12	Polymorphisms in base-excision repair and nucleotide-excision repair genes in relation to lung cancer risk. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2007, 631, 101-110.	0.9	194
13	PALB2,CHEK2andATMrare variants and cancer risk: data from COGS. Journal of Medical Genetics, 2016, 53, 800-811.	1.5	174
14	Common Breast Cancer Susceptibility Alleles and the Risk of Breast Cancer for BRCA1 and BRCA2 Mutation Carriers: Implications for Risk Prediction. Cancer Research, 2010, 70, 9742-9754.	0.4	169
15	Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores. Journal of Clinical Oncology, 2017, 35, 2240-2250.	0.8	152
16	Genotype-Phenotype Correlation in NF1: Evidence for a More Severe Phenotype Associated with Missense Mutations Affecting NF1 Codons 844â€“848. American Journal of Human Genetics, 2018, 102, 69-87.	2.6	144
17	High Incidence of Noonan Syndrome Features Including Short Stature and Pulmonic Stenosis in Patients carrying NF1 Missense Mutations Affecting p.Arg1809: Genotypeâ€“Phenotype Correlation. Human Mutation, 2015, 36, 1052-1063.	1.1	143
18	Spectrum of single- and multiexon NF1 copy number changes in a cohort of 1,100 unselected NF1 patients. Genes Chromosomes and Cancer, 2006, 45, 265-276.	1.5	129

#	Article	IF	Citations
19	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. Nature Genetics, 2016, 48, 374-386.	9.4	125
20	Chromosomal radiosensitivity in breast cancer patients with a known or putative genetic predisposition. British Journal of Cancer, 2002, 87, 1379-1385.	2.9	122
21	Glomus Tumors in Neurofibromatosis Type 1: Genetic, Functional, and Clinical Evidence of a Novel Association. Cancer Research, 2009, 69, 7393-7401.	0.4	122
22	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. Nature Genetics, 2020, 52, 56-73.	9.4	120
23	Radiation-induced damage to normal tissues after radiotherapy in patients treated for gynecologic tumors: Association with single nucleotide polymorphisms in XRCC1, XRCC3, and OGG1 genes and in vitro chromosomal radiosensitivity in lymphocytes. International Journal of Radiation Oncology Biology Physics, 2005, 62, 1140-1149.	0.4	114
24	Acute Normal Tissue Reactions in Head-and-Neck Cancer Patients Treated With IMRT: Influence of Dose and Association With Genetic Polymorphisms in DNA DSB Repair Genes. International Journal of Radiation Oncology Biology Physics, 2009, 73, 1187-1195.	0.4	113
25	Rapid detection of VHL exon deletions using real-time quantitative PCR. Laboratory Investigation, 2005, 85, 24-33.	1.7	102
26	The Exon 13 Duplication in the BRCA1 Gene Is a Founder Mutation Present in Geographically Diverse Populations. American Journal of Human Genetics, 2000, 67, 207-212.	2.6	100
27	Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. Human Molecular Genetics, 2009, 18, 4442-4456.	1.4	99
28	Comparison of mRNA Splicing Assay Protocols across Multiple Laboratories: Recommendations for Best Practice in Standardized Clinical Testing. Clinical Chemistry, 2014, 60, 341-352.	1.5	95
29	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. Nature Communications, 2016, 7, 11375.	5.8	93
30	The genetic basis of undiagnosed muscular dystrophies and myopathies. Neurology, 2016, 87, 71-76.	1.5	92
31	Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. Nature Communications, 2019, 10, 1741.	5.8	90
32	Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Research, 2016, 18, 15.	2.2	88
33	Shared heritability and functional enrichment across six solid cancers. Nature Communications, 2019, 10, 431.	5.8	88
34	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. Genetics in Medicine, 2020, 22, 1653-1666.	1.1	82
35	Clinical spectrum of individuals with pathogenic N F1 missense variants affecting p.Met1149, p.Arg1276, and p.Lys1423: genotypeâ€“phenotype study in neurofibromatosis type 1. Human Mutation, 2020, 41, 299-315.	1.1	80
36	Differentiating pathogenic mutations from polymorphic alterations in the splice sites ofBRCA1 andBRCA2. Genes Chromosomes and Cancer, 2003, 37, 314-320.	1.5	78

#	Article	IF	Citations
37	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breastâ€“ovarian cancer susceptibility locus. Nature Communications, 2016, 7, 12675.	5.8	78
38	BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. Journal of the National Cancer Institute, 2016, 108, djv315.	3.0	77
39	DNA Diagnostics of Hereditary Hearing Loss: A Targeted Resequencing Approach Combined with a Mutation Classification System. Human Mutation, 2016, 37, 812-819.	1.1	76
40	BRCA2 Hypomorphic Missense Variants Confer Moderate Risks of Breast Cancer. Cancer Research, 2017, 77, 2789-2799.	0.4	75
41	A Homozygous MSH6 Mutation in a Child with CafÃ©-au-Lait Spots, Oligodendroglioma and Rectal Cancer. Familial Cancer, 2002, 3, 123-127.	0.9	74
42	Leiden open variation database of the MUTYH gene. Human Mutation, 2010, 31, 1205-1215.	1.1	72
43	Rapid and Sensitive Detection of BRCA1/2 Mutations in a Diagnostic Setting: Comparison of Two High-Resolution Melting Platforms. Clinical Chemistry, 2008, 54, 982-989.	1.5	65
44	Next generation sequencing on patients with LGMD and nonspecific myopathies: Findings associated with ANO5 mutations. Neuromuscular Disorders, 2015, 25, 533-541.	0.3	65
45	Chromosomal radiosensitivity in BRCA1 and BRCA2 mutation carriers. International Journal of Radiation Biology, 2004, 80, 745-756.	1.0	64
46	Spectrum and characterisation of BRCA1 and BRCA2deleterious mutations in high-risk Czech patients with breast and/or ovarian cancer. BMC Cancer, 2008, 8, 140.	1.1	64
47	Dominant-negative mutations in human IL6ST underlie hyper-IgE syndrome. Journal of Experimental Medicine, 2020, 217, .	4.2	64
48	A replication study confirms the association of TNFSF4 (OX40L) polymorphisms with systemic sclerosis in a large European cohort. Annals of the Rheumatic Diseases, 2011, 70, 638-641.	0.5	63
49	SVA retrotransposon insertion-associated deletion represents a novel mutational mechanism underlying large genomic copy number changes with non-recurrent breakpoints. Genome Biology, 2014, 15, R80.	13.9	63
50	Cancer Surveillance Guideline for individuals with PTEN hamartoma tumour syndrome. European Journal of Human Genetics, 2020, 28, 1387-1393.	1.4	63
51	Expanding the clinical phenotype of individuals with a 3-bp in-frame deletion of the NF1 gene (c.2970_2972del): an update of genotypeâ€“phenotype correlation. Genetics in Medicine, 2019, 21, 867-876.	1.1	62
52	A sensitive and specific diagnostic test for hearing loss using a microdroplet PCRâ€based approach and next generation sequencing. American Journal of Medical Genetics, Part A, 2013, 161, 145-152.	0.7	61
53	A multicentric, international matched pair analysis of body composition in peritoneal dialysis versus haemodialysis patients. Nephrology Dialysis Transplantation, 2013, 28, 2620-2628.	0.4	61
54	Common variants associated with breast cancer in genome-wide association studies are modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers. Human Molecular Genetics, 2010, 19, 2886-2897.	1.4	60

#	Article	IF	Citations
55	Massive parallel amplicon sequencing of the breast cancer genes BRCA1 and BRCA2: opportunities, challenges, and limitations. Human Mutation, 2011, 32, 335-344.	1.1	58
56	TGFÎ²1 polymorphisms and late clinical radiosensitivity in patients treated for gynecologic tumors. International Journal of Radiation Oncology Biology Physics, 2006, 65, 1240-1248.	0.4	57
57	Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research, 2014, 16, 3416.	2.2	57
58	TIM3+ TRBV11-2 T cells and IFNÎ³ signature in patrolling monocytes and CD16+ NK cells delineate MIS-C. Journal of Experimental Medicine, 2022, 219, .	4.2	57
59	Comparison of microsatellite instability detection by immunohistochemistry and molecular techniques in colorectal and endometrial cancer. Scientific Reports, 2021, 11, 12880.	1.6	55
60	A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Research, 2018, 78, 5419-5430.	0.4	54
61	Polymorphisms in nonhomologous endâ€joining genes associated with breast cancer risk and chromosomal radiosensitivity. Genes Chromosomes and Cancer, 2008, 47, 137-148.	1.5	51
62	The BRCA1 c. 5096G>A p.Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA consortium. Journal of Medical Genetics, 2018, 55, 15-20.	1.5	50
63	Characterization of the Cancer Spectrum in Men With GermlineBRCA1andBRCA2Pathogenic Variants. JAMA Oncology, 2020, 6, 1218.	3.4	48
64	Polymorphisms in the lectin pathway genes as a possible cause of early chronic Pseudomonas aeruginosa colonization in cystic fibrosis patients. Human Immunology, 2012, 73, 1175-1183.	1.2	47
65	DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. PLoS Genetics, 2014, 10, e1004256.	1.5	47
66	BRCA1 and BRCA2 germline mutation spectrum and frequencies in Belgian breast/ovarian cancer families. British Journal of Cancer, 2004, 90, 1244-1251.	2.9	46
67	Questioning the Pathogenic Role of the GLA p.Ala143Thr â€œMutationâ€•in Fabry Disease: Implications for Screening Studies and ERT. JIMD Reports, 2012, 8, 101-108.	0.7	44
68	Mutation analysis of RAD51D in non-BRCA1/2 ovarian and breast cancer families. British Journal of Cancer, 2012, 106, 1460-1463.	2.9	43
69	Flexible, Scalable, and Efficient Targeted Resequencing on a Benchtop Sequencer for Variant Detection in Clinical Practice. Human Mutation, 2015, 36, 379-387.	1.1	43
70	Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women. Breast Cancer Research, 2016, 18, 112.	2.2	42
71	BRCA1, BRCA2 and PALB2 mutations and CHEK2 c.1100delC in different South African ethnic groups diagnosed with premenopausal and/or triple negative breast cancer. BMC Cancer, 2015, 15, 912.	1.1	41
72	Practical Tools to Implement Massive Parallel Pyrosequencing of PCR Products in Next Generation Molecular Diagnostics. PLoS ONE, 2011, 6, e25531.	1.1	40

#	Article	IF	Citations
73	Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness. Cancer Research, 2020, 80, 624-638.	0.4	39
74	Pathological splice mutations outside the invariant AG/GT splice sites of BRCA1 exon 5 increase alternative transcript levels in the 5â€² end of the BRCA1 gene. Oncogene, 2002, 21, 4171-4175.	2.6	35
75	Assessing Associations between the AURKA-HMMR-TPX2-TUBG1 Functional Module and Breast Cancer Risk in BRCA1/2 Mutation Carriers. PLoS ONE, 2015, 10, e0120020.	1.1	34
76	Jaffeâ€“Campanacci syndrome, revisited: detailed clinical and molecular analyses determine whether patients have neurofibromatosis type 1, coincidental manifestations, or a distinct disorder. Genetics in Medicine, 2014, 16, 448-459.	1.1	33
77	Mate pair sequencing for the detection of chromosomal aberrations in patients with intellectual disability and congenital malformations. European Journal of Human Genetics, 2014, 22, 652-659.	1.4	32
78	Non Coding RNA Molecules as Potential Biomarkers in Breast Cancer. Advances in Experimental Medicine and Biology, 2015, 867, 263-275.	0.8	32
79	Transcriptomeâ€wide association study of breast cancer risk by estrogenâ€receptor status. Genetic Epidemiology, 2020, 44, 442-468.	0.6	32
80	Two-tier approach for the detection of alpha-galactosidase A deficiency in a predominantly female haemodialysis population. Nephrology Dialysis Transplantation, 2007, 23, 294-300.	0.4	31
81	Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. Breast Cancer Research, 2016, 18, 64.	2.2	31
82	Functional redundancy of exon 12 ofBRCA2revealed by a comprehensive analysis of the c.6853A>G (p.I2285V) variant. Human Mutation, 2009, 30, 1543-1550.	1.1	30
83	Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study. Journal of the National Cancer Institute, 2019, 111, 350-364.	3.0	30
84	Prevalence of BRCA1/2 mutations in sporadic breast/ovarian cancer patients and identification of a novel de novo BRCA1 mutation in a patient diagnosed with late onset breast and ovarian cancer: implications for genetic testing. Breast Cancer Research and Treatment, 2012, 132, 87-95.	1.1	29
85	Variant Ataxia Telangiectasia: Clinical and Molecular Findings and Evaluation of Radiosensitive Phenotypes in a Patient and Relatives. NeuroMolecular Medicine, 2013, 15, 447-457.	1.8	29
86	Dealing with Pseudogenes in Molecular Diagnostics in the Next-Generation Sequencing Era. Methods in Molecular Biology, 2014, 1167, 303-315.	0.4	29
87	Benign retroperitoneal schwannoma presenting as colitis: A case report. World Journal of Gastroenterology, 2007, 13, 5521.	1.4	29
88	THE RATE OF GASTRIC EMPTYING DETERMINES THE TIMING BUT NOT THE EXTENT OF ORAL TACROLIMUS ABSORPTION: SIMULTANEOUS MEASUREMENT OF DRUG EXPOSURE AND GASTRIC EMPTYING BY CARBON-14-OCTANOIC ACID BREATH TEST IN STABLE RENAL ALLOGRAFT RECIPIENTS. Drug Metabolism and Disposition, 2004, 32, 1421-1425.	1.7	28
89	<i>IRF6</i> Screening of Syndromic and a priori Non-Syndromic Cleft Lip and Palate Patients: Identification of a New Type of Minor VWS Sign. Molecular Syndromology, 2010, 1, 67-74.	0.3	28
90	Characterization of the nonallelic homologous recombination hotspot PRS3 associated with type-3NF1deletions. Human Mutation, 2012, 33, 372-383.	1.1	28

#	Article	IF	Citations
91	The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer. Npj Breast Cancer, 2019, 5, 38.	2.3	28
92	The Zebrafish as an Emerging Model to Study DNA Damage in Aging, Cancer and Other Diseases. Frontiers in Cell and Developmental Biology, 2018, 6, 178.	1.8	28
93	Shallow whole-genome sequencing of plasma cell-free DNA accurately differentiates small from non-small cell lung carcinoma. Genome Medicine, 2020, 12, 35.	3.6	28
94	Mutation Analysis of the BRCA1 and BRCA2 Genes in the Belgian Patient Population and Identification of a Belgian Founder Mutation BRCA1 IVS5+3A>G. Disease Markers, 1999, 15, 69-73.	0.6	27
95	Combined effect of polymorphisms in Rad51 and Xrcc3 on breast cancer risk and chromosomal radiosensitivity. Molecular Medicine Reports, 2011, 4, 901-12.	1.1	27
96	Mitotic recombination of chromosome arm 17q as a cause of loss of heterozygosity of NF1 in neurofibromatosis type 1â€associated glomus tumors. Genes Chromosomes and Cancer, 2012, 51, 429-437.	1.5	27
97	Identification of recurrent type-2NF1microdeletions reveals a mitotic nonallelic homologous recombination hotspot underlying a human genomic disorder. Human Mutation, 2012, 33, 1599-1609.	1.1	26
98	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. Breast Cancer Research, 2015, 17, 61.	2.2	26
99	An international survey of surveillance schemes for unaffected BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment, 2016, 157, 319-327.	1.1	26
100	Analysis of chromosomal radiosensitivity of healthy BRCA2 mutation carriers and non-carriers in BRCA families with the G2 micronucleus assay. Oncology Reports, 2017, 37, 1379-1386.	1.2	26
101	Increased chromosomal radiosensitivity in asymptomatic carriers of a heterozygous BRCA1 mutation. Breast Cancer Research, 2016, 18, 52.	2.2	25
102	Decoding NF1 Intragenic Copy-Number Variations. American Journal of Human Genetics, 2015, 97, 238-249.	2.6	24
103	Evaluation of RAD51C as cancer susceptibility gene in a large breast-ovarian cancer patient population referred for genetic testing. Breast Cancer Research and Treatment, 2012, 133, 393-398.	1.1	23
104	Polygenic risk modeling for prediction of epithelial ovarian cancer risk. European Journal of Human Genetics, 2022, 30, 349-362.	1.4	23
105	Mutation analysis of the BRCA1 and BRCA2 genes results in the identification of novel and recurrent mutations in 6/16 Flemish families with breast and/or ovarian cancer but not in 12 sporadic patients with early-onset disease. , 1999, 13, 256-256.		22
106	Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 308-316.	1.1	22
107	Genotyping of Frequent BRCA1/2 SNPs with Unlabeled Probes. Journal of Molecular Diagnostics, 2009, 11, 415-419.	1.2	21
108	Analysis of the Novel Fanconi Anemia GeneSLX4/FANCPin Familial Breast Cancer Cases. Human Mutation, 2013, 34, 70-73.	1.1	21

#	Article	IF	Citations
109	Microsatellite instability in sporadic colon carcinomas has no independent prognostic value in a Belgian study population. European Journal of Cancer, 2008, 44, 2288-2295.	1.3	19
110	Genetic Testing and Clinical Management Practices for Variants in Non-BRCA1/2 Breast (and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 712 for the Interpretation of Germline Mutant Alleles (ENIGMA) Clinical Working Group. JCO Precision Oncology, 2018, 2, 1-42.	1.5	19
111	Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. British Journal of Cancer, 2019, 121, 180-192.	2.9	19
112	A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. Nature Communications, 2021, 12, 1078.	5.8	19
113	Breast and Prostate Cancer Risks for MaleBRCA1andBRCA2Pathogenic Variant Carriers Using Polygenic Risk Scores. Journal of the National Cancer Institute, 2022, 114, 109-122.	3.0	19
114	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecologic Oncology, 2016, 141, 386-401.	0.6	18
115	Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. Breast Cancer Research and Treatment, 2017, 161, 117-134.	1.1	18
116	Two-tier approach for the detection of alpha-galactosidase A deficiency in kidney transplant recipients. Nephrology Dialysis Transplantation, 2008, 23, 4044-4048.	0.4	17
117	Boosting care and knowledge about hereditary cancer: European Reference Network on Genetic Tumour Risk Syndromes. Familial Cancer, 2019, 18, 281-284.	0.9	17
118	The predictive ability of the 313 variantâ€“based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. Genetics in Medicine, 2021, 23, 1726-1737.	1.1	16
119	Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA). British Journal of Cancer, 2009, 101, 2048-2054.	2.9	15
120	BRCA1 and BRCA2 5â€² noncoding region variants identified in breast cancer patients alter promoter activity and protein binding. Human Mutation, 2018, 39, 2025-2039.	1.1	15
121	Long term response on Regorafenib in non-V600E BRAF mutated colon cancer: a case report. BMC Cancer, 2019, 19, 567.	1.1	15
122	Chromosomal radiosensitivity of breast cancer with a mutation. Cancer Genetics and Cytogenetics, 2005, 163, 106-112.	1.0	13
123	Palindrome-Mediated and Replication-Dependent Pathogenic Structural Rearrangements within theNF1Gene. Human Mutation, 2014, 35, 891-898.	1.1	13
124	Extreme clustering of type-1 NF1 deletion breakpoints co-locating with G-quadruplex forming sequences. Human Genetics, 2018, 137, 511-520.	1.8	13
125	Shallow-depth sequencing of cell-free DNA for Hodgkin and diffuse large B-cell lymphoma (differential) diagnosis: a standardized approach with underappreciated potential. Haematologica, 2020, Online ahead of print, 0-0.	1.7	13
126	Evaluation of relative quantification of alternatively spliced transcripts using droplet digital PCR. Biomolecular Detection and Quantification, 2017, 13, 40-48.	7.0	12

#	Article	IF	Citations
127	Accurate detection and quantification of epigenetic and genetic second hits in BRCA1 and BRCA2 -associated hereditary breast and ovarian cancer reveals multiple co-acting second hits. Cancer Letters, 2018, 425, 125-133.	3.2	12
128	Diagnosis of Fanconi Anaemia by ionising radiation- or mitomycin C-induced micronuclei. DNA Repair, 2018, 61, 17-24.	1.3	12
129	Enhanced MCP-1 Release in Early Autosomal Dominant Polycystic Kidney Disease. Kidney International Reports, 2021, 6, 1687-1698.	0.4	12
130	Next Generation Sequencing to Determine the Cystic Fibrosis Mutation Spectrum in Palestinian Population. Disease Markers, 2015, 2015, 1-6.	0.6	11
131	Focus on 16p13.3 Locus in Colon Cancer. PLoS ONE, 2015, 10, e0131421.	1.1	11
132	The genetics of familial adenomatous polyposis (FAP) and MutYH-associated polyposis (MAP). Acta Gastro-Enterologica Belgica, 2011, 74, 421-6.	0.4	11
133	Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. PLoS ONE, 2016, 11, e0158801.	1.1	10
134	Multiple orbital neurofibromas, painful peripheral nerve tumors, distinctive face and marfanoid habitus: a new syndrome. European Journal of Human Genetics, 2012, 20, 618-625.	1.4	9
135	Accurate quantification of homologous recombination in zebrafish: brca2 deficiency as a paradigm. Scientific Reports, 2017, 7, 16518.	1.6	9
136	Joint Belgian recommendation on screening for DPD-deficiency in patients treated with 5-FU, capecitabine (and tegafur). Acta Clinica Belgica, 2021, , 1-7.	0.5	9
137	Pathogenic neurofibromatosis type 1 (NF1) RNA splicing resolved by targeted RNAseq. Npj Genomic Medicine, 2021, 6, 95.	1.7	9
138	Prostate cancer in Cowden syndrome: somatic loss and germline mutation of the PTEN gene. Cancer Genetics, 2011, 204, 224-225.	0.2	8
139	Prevalence of Germline Pathogenic Variants in Cancer Predisposing Genes in Czech and Belgian Pancreatic Cancer Patients. Cancers, 2021, 13, 4430.	1.7	8
140	Somatic mosaics in hereditary tumor predisposition syndromes. European Journal of Medical Genetics, 2021, 64, 104360.	0.7	8
141	Radiation-induced myosin IIA expression stimulates collagen type I matrix reorganization. Radiotherapy and Oncology, 2013, 108, 162-167.	0.3	7
142	Genetic Counselling and Testing for Hereditary Breast and Ovarian Cancer: The Gent(le) Approach. Disease Markers, 1999, 15, 191-195.	0.6	5
143	Thorough in silico and in vitro cDNA analysis of 21 putativeBRCA1andBRCA2splice variants and a complex tandem duplication inBRCA2allowing the identification of activated cryptic splice donor sites inBRCA2exon 11. Human Mutation, 2018, 39, 515-526.	1.1	5
144	Germline Genetic Findings Which May Impact Therapeutic Decisions in Families with a Presumed Predisposition for Hereditary Breast and Ovarian Cancer. Cancers, 2020, 12, 2151.	1.7	5

#	Article	IF	Citations
145	Myxoid hepatocellular adenoma, a rare variant of hepatocellular adenoma with distinct imaging features: A case report with immunohistochemical and molecular analysis and literature review. Clinics and Research in Hepatology and Gastroenterology, 2021, 45, 101478.	0.7	5
146	Twenty Years of BRCA1 and BRCA2 Molecular Analysis at MMCI â€“ Current Developments for the Classifi cation of Variants. Klinicka Onkologie, 2019, 32, 51-71.	0.1	5
147	An abnormally glycosylated isoform of erythropoietin in hemangioblastoma is associated with polycythemia. Clinica Chimica Acta, 2015, 438, 304-306.	0.5	3
148	Incorporating PARP-inhibitors into clinical routine: A tailored treatment strategy to tackle ovarian cancer. Acta Clinica Belgica, 2017, 72, 6-11.	0.5	3
149	Missing heritability in Bloom syndrome: First report of a deep intronic variant leading to pseudoâ€exon activation in the <scp>BLM</scp> gene. Clinical Genetics, 2021, 99, 292-297.	1.0	3
150	Application of an Ultrasensitive NGS-Based Blood Test for the Diagnosis of Early-Stage Lung Cancer: Sensitivity, a Hurdle Still Difficult to Overcome. Cancers, 2022, 14, 2031.	1.7	3
151	Objective assessment of nasality in flemish adults with neurofibromatosis type 1. American Journal of Medical Genetics, Part A, 2011, 155, 2974-2981.	0.7	2
152	Lhermitte-Duclos disease with obstructive hydrocephalus: An illustrative case treated with endoscopic ventriculo-cisternostomy. Revue Neurologique, 2013, 169, 917-919.	0.6	2
153	Chromosomal radiosensitivity of triple negative breast cancer patients. International Journal of Radiation Biology, 2019, 95, 1507-1516.	1.0	2
154	Zebrafish as an in vivo screening tool to establish PARP inhibitor efficacy. DNA Repair, 2021, 97, 103023.	1.3	2
155	Breast-Cancer Risk in Families With Mutations in PALB2. Obstetrical and Gynecological Survey, 2014, 69, 659-660.	0.2	1
156	Timing of blood sampling for butyrylcholinesterase phenotyping in patients with prolonged neuromuscular block after mivacurium or suxamethonium. Acta Anaesthesiologica Scandinavica, 2021, 65, 182-187.	0.7	1
157	Dealing with Pseudogenes in Molecular Diagnostics in the Next Generation Sequencing Era. Methods in Molecular Biology, 2021, 2324, 363-381.	0.4	1
158	Midline nasal dermoid sinus cyst in basal cell naevus syndrome (BCNS or Gorlin syndrome): A case report and review. International Journal of Pediatric Otorhinolaryngology Extra, 2012, 7, 119-121.	0.1	0
159	Second hit landscape in BRCA1/2-associated breast cancer. Annals of Oncology, 2017, 28, i9.	0.6	0
160	Hereditary Syndromes and Pancreatic Cancer. , 2021, , 29-49.		0
161	Frequency of Participation in External Quality Assessment Programs Focused on Rare Diseases: Belgian Guidelines for Human Genetics Centers. JMIR Medical Informatics, 2021, 9, e27980.	1.3	0
162	Decreased DNA doubleâ€strand break repair and enhanced chromosomal radiosensitivity in irradiated nonâ€tumorigenic human breast epithelial cells with a partial BRCA1 or BRCA2 knockdown. World Academy of Sciences Journal, 0, , .	0.4	0

#	Article	IF	Citations
163	Atm deficient zebrafish model reveals conservation of the tumour suppressor function and a role in fertility. Genes and Diseases, 2023, 10, 381-384.	1.5	0